Drug Delivery Resource Center


White Papers: In Depth Research

  • Avoiding No Man's Land: Potential Unintended Consequences of Follow-On Biologics

    Author: Deloitte

    Still, the essential debate encompasses two broad issues: patient safety and industry economics. This paper from Deloitte explores what will constitute threshold biosimilarity? The definition of biosimilarity is likely to involve standards regarding the de

  • Best Practices in Demand and Inventory Planning

    Author: CDC Software

    It's a classic scenario in pharmaceutical manufacturing, struggling to coordinate the opinions of sales and marketing with clinical opportunities and manufacturing/supply chain initiatives on what, when, and where a product should be produced. This white p

  • SAP Support of the Healthcare Supply Chain’s Ongoing Effort to Ensure Patient Safety and Drive Business Value

    Author: SAP

    This white paper provides a detailed look at SAP’s support for the Center for Healthcare Supply Chain Research Blueprint for Data Management & Data Sharing. It also offers a summary of the Blueprint concepts and a review short- and long-term business

  • Residual Solvents by HT3 Headspace in Reference to USP 467

    Author: Teledyne Tekmar

    Residual solvents in pharmaceuticals are defined as volatile organic chemicals that are used or produced in the manufacture of drug substances, excipients or in the preparation of drug products. Because residual solvents do not provide therapeutic benefits